Grant Yonehiro

Grant Yonehiro's Title

Grant Yonehiro serves as the Chief Business Officer at Bolt Biotherapeutics, a position he has held since joining the company in 2016. As Chief Business Officer, Yonehiro plays a crucial role in steering the company's strategic direction, overseeing business development activities, and driving corporate growth initiatives. His extensive experience in biotechnology and business management uniquely positions him to lead Bolt Biotherapeutics through its various growth phases and commercialization efforts.

Grant Yonehiro's Experience

Grant Yonehiro boasts over 25 years of extensive experience in business and corporate development, strategy, commercialization, and general management within the biotechnology sector. His career includes notable roles such as serving as President and Chief Executive Officer of Perseid Therapeutics, where he led the company from its inception through its acquisition by Astellas Pharma. He continued his leadership as President of an Astellas operating site post-acquisition. Yonehiro has also held senior executive positions at Berkeley Lights, Maxygen Inc., and GenVec, Inc., contributing significantly to their business operations and strategic growth.

Grant Yonehiro's Education and Expertise

Grant Yonehiro graduated magna cum laude from the University of Minnesota with a Bachelor of Individualized Studies, showcasing his academic excellence early on. He further advanced his expertise by obtaining an MBA from the prestigious Haas School of Business at the University of California, Berkeley. This strong educational foundation, combined with his diverse professional experiences, equips him with a unique blend of skills in business strategy, corporate development, and biotechnology commercialization.

Grant Yonehiro's Background

Grant Yonehiro's career began in investment banking at Piper Jaffray, where he gained valuable financial and strategic insights. He then transitioned to the biotechnology sector, working in business development at Cell Genesys, Inc., and in the Technology Transfer Office at Lawrence Berkeley National Laboratory. These roles provided him with a well-rounded perspective on the intersection of technology, business, and science, laying the groundwork for his future leadership positions in high-profile biotech companies.

Grant Yonehiro's Achievements

Throughout his career, Grant Yonehiro has achieved significant milestones, including leading Perseid Therapeutics from inception through its acquisition by Astellas Pharma. His leadership and strategic vision were instrumental in the successful transition and continued growth of the company post-acquisition. At Bolt Biotherapeutics, he continues to drive impactful business development and corporate strategies. Yonehiro's contributions to the biotech industry are marked by his ability to navigate complex business landscapes and foster growth and innovation.